Deanna Fussy
Family · Glendale, AZNPI 1972100097
Payments from drug & device makers
Across 107 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$542
- Novartis$359
- Amgen$301
- AstraZeneca$238
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$151
- Boston Scientific$147
- plus $339 from 10 others
What the payments were for
- Food & beverage$2,01697%
- Education$603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 9 | $542 |
| Novartis | 29 | $359 |
| Amgen | 21 | $301 |
| AstraZeneca | 5 | $238 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $151 |
| Boston Scientific | 7 | $147 |
| Impulse Dynamics (USA) Inc. | 11 | $110 |
| Boehringer Ingelheim | 4 | $76 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Cvrx, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
| Lundbeck LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,076 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $20,722 |
| ClopidogrelClopidogrel Bisulfate | 19 | $269 |
| Atorvastatin Calcium | 18 | $209 |
| Rosuvastatin Calcium | 17 | $124 |
| Amlodipine Besylate | 17 | $111 |
| Losartan Potassium | 17 | $100 |
| Carvedilol | 12 | $99 |
Paid to pharmacies, not to this prescriber.
Other family in Glendale
- Kelci HunterGlendale$19K
- Amber BerleenGlendale$16K
- Ashley SchohnGlendale$16K
- Bettina SiebeneckGlendale$15K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.